Clinical Trials Logo

Hepatocellular Carcinoma clinical trials

View clinical trials related to Hepatocellular Carcinoma.

Filter by:

NCT ID: NCT03781960 Terminated - Clinical trials for Hepatocellular Carcinoma

Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma

Start date: July 31, 2019
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to evaluate the effectiveness of the combination of nivolumab and abemaciclib for the treatment of hepatocellular carcinoma. Other goals of this study are to learn about the side effects that this combination of drugs may cause and to learn more about how these drugs work by studying blood and tissue.

NCT ID: NCT03781934 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations

Start date: September 5, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, multicentre dose escalation/expansion study to assess safety and tolerability of MIV 818 as either monotherapy or in combination with 1) lenvatinib, a tyrosine kinase inhibitor used as a standard of care for the treatment of HCC or 2) pembrolizumab, a PD-1 inhibitor. The monotherapy parts of the study will include patients with various solid tumours that have spread to the liver, or alternatively originating in the liver. Evaluations of MIV-818 in combination with lenvatinib or pembrolizumab will only include patients with HCC.

NCT ID: NCT03780634 Withdrawn - Clinical trials for Hepatocellular Carcinoma

HAIC Plus PD-1 Antibody vs HAIC Plus Sorafenib for Advanced HCC

Start date: April 1, 2019
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of hepatic artery infusion chemotherapy (HAIC) combined with Programmed Cell Death Protein-1 (PD-1) antibody compared with HAIC plus sorafenib in patients with advanced hepatocellular carcinoma (HCC)

NCT ID: NCT03780049 Recruiting - Clinical trials for Hepatocellular Carcinoma

HAIC Plus H101 vs HAIC Alone for Unresectable HCC at BCLC A-B

Start date: October 1, 2018
Phase: Phase 3
Study type: Interventional

Hepatic artery infusion chemotherapy (HAIC) is effective and safe for hepatocellular carcinoma (HCC). Recombinant Human Type-5 Adenovirus (H101) is safe for HCC. The purpose of this study is to evaluate the efficacy and safety of HAIC combined with H101 compared with HAIC alone in patients with unresectable hepatocellular carcinoma (HCC) at barcelona clinic liver cancer A-B stage.

NCT ID: NCT03778957 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma

EMERALD-1
Start date: November 30, 2018
Phase: Phase 3
Study type: Interventional

A global study to evaluate transarterial chemoembolization (TACE) in combination with durvalumab and bevacizumab therapy in patients with locoregional hepatocellular carcinoma

NCT ID: NCT03777475 Recruiting - Clinical trials for Hepatocellular Carcinoma

the Effect of Different Oxaliplatin Dose in Transarterial Infusion (TAI) in Unresectable Hepatocellular Carcinoma

Start date: July 1, 2016
Phase: N/A
Study type: Interventional

evaluate the effect of different oxaliplatin dose in TAI in treating unresectable HCC.

NCT ID: NCT03776123 Completed - Clinical trials for Hepatocellular Carcinoma

Post-marketing Surveillance on the Safety of CabometyxTM in Korean Patients

Start date: May 15, 2019
Phase:
Study type: Observational

The objective of this Post Marketing Surveillance (PMS) is to collect and describe safety and effectiveness profile of Cabometyxâ„¢ in real clinical practice setting, according to the approved labelling after the approval of marketing authorization.

NCT ID: NCT03775707 Withdrawn - Clinical trials for Hepatocellular Carcinoma

Lenvatinib Plus PD-1 Antibody for Intermediate-stage HCC Beyond Up-to-seven Criteria

Start date: December 1, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of lenvatinib combined with PD-1 antibody for patients with intermediate-stage hepatocellular carcinoma (HCC) beyond up-to-seven criteria

NCT ID: NCT03775395 Recruiting - Clinical trials for Hepatocellular Carcinoma

HAIC Plus Lenvatinib vs HAIC Plus Sorafenib for Advanced HCC

Start date: December 12, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of sorafenib combined with hepatic arterial infusion chemotherapy (HAIC) compared with lenvatinib combined with HAIC in patients with advanced hepatocellular carcinoma (HCC)

NCT ID: NCT03767764 Completed - Clinical trials for Hepatocellular Carcinoma

Yliver as a Test to Early Diagnose HCC

YliverDIAG
Start date: December 27, 2018
Phase:
Study type: Observational

Liver cancer (HCC) is the second cause of death related to cancer worldwide, with about 750,000 deaths from this cause in 2012. Although the early diagnosis of liver cancer increases the available treatment options, the methods currently used for screening are not sufficiently sensitive for this purpose. The investigators provide a high-performance and highly reliable in vitro platform that allows the identification and quantification of autoantibodies in serum for use as biomarkers of liver cancer, using an ELISA test (Yliver). The aim of the study is to demonstrate whether the Yliver test can be used as a biomarker for the early diagnosis of hepatocellular carcinoma with a collection of samples from 58 patients diagnosed with HCC, 42 cirrhosis, 40 normal controls and the inclusion of 25-50 patients with chronic liver disease without cirrhosis.